alendronate has been researched along with Venous Thromboembolism in 4 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Venous Thromboembolism: Obstruction of a vein or VEINS (embolism) by a blood clot (THROMBUS) in the blood stream.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We aimed to compare the risk of venous thromboembolism (VTE) among incident users of different AOM compared to alendronate (first line therapy)." | 3.88 | Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK. ( Álvarez-Gutierrez, A; Cooper, C; Delmestri, A; Hawley, S; Javaid, MK; Judge, A; Khalid, S; Llorente-Garcia, A; Martín-Merino, E; Petersen, I; Prieto-Alhambra, D; Van Staa, TP, 2018) |
| "This retrospective analysis found that the incidence of VTE in Taiwanese patients with osteoporosis was low, and the risk of VTE was similar across alendronate, raloxifene, and calcitonin recipients in patients with osteoporotic fractures who were new to osteoporosis therapy." | 3.80 | Incidence and risk of venous thromboembolism among Taiwan osteoporotic fracture population under osteoporosis pharmacological treatments. ( Lee, CH; Lin, SJ; Lin, TC; Yang, CY; Yang, YH, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Martín-Merino, E | 1 |
| Petersen, I | 1 |
| Hawley, S | 1 |
| Álvarez-Gutierrez, A | 1 |
| Khalid, S | 1 |
| Llorente-Garcia, A | 1 |
| Delmestri, A | 1 |
| Javaid, MK | 1 |
| Van Staa, TP | 1 |
| Judge, A | 1 |
| Cooper, C | 2 |
| Prieto-Alhambra, D | 1 |
| Lin, TC | 1 |
| Lee, CH | 1 |
| Yang, CY | 1 |
| Yang, YH | 1 |
| Lin, SJ | 1 |
| Kaehling, Ch | 1 |
| Streckbein, P | 1 |
| Schmermund, D | 1 |
| Henrich, M | 1 |
| Burchert, D | 1 |
| Gattenloehner, S | 1 |
| Howaldt, HP | 1 |
| Wilbrand, JF | 1 |
| Breart, G | 1 |
| Meyer, O | 1 |
| Speirs, C | 1 |
| Deltour, N | 1 |
| Reginster, JY | 1 |
4 other studies available for alendronate and Venous Thromboembolism
| Article | Year |
|---|---|
Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; D | 2018 |
Incidence and risk of venous thromboembolism among Taiwan osteoporotic fracture population under osteoporosis pharmacological treatments.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Female; Humans; | 2014 |
Lethal cervical abscess following bisphosphonate related osteonecrosis of the jaw.
Topics: Abscess; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation | 2014 |
Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Epidemiologic Methods; Femal | 2010 |